{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"11","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Time to neutrophil engraftment is defined as duration between Day 0 to the first day of ANC \\> 0.5x109/L post transplant when it is sustained for more than three consecutive days.","dispersionType":"Full Range","groups":[{"description":"Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0","id":"OG000","title":"V-BEAM + Stem Cell Infusion"}],"paramType":"MEDIAN","populationDescription":"Two participants without evaluable responses due to early mortality were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"Day +100","title":"Time to Neutrophil Engraftment After V-BEAM.","type":"SECONDARY","unitOfMeasure":"days"}